Last update 16 Nov 2024

ET190L1-ARTEMIS T cells(Eureka Therapeutics, Inc.)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
ET190L1-AbTCR T-cells, ET190L1-ARTEMIS T cells, ET 190
+ [5]
Target
CD19
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
B-Cell LymphomaCD19 Positive B-Cell LeukemiaCD19 positive B-Cell Lymphoma
Originator Organization
Eureka Therapeutics, Inc.Eureka Therapeutics, Inc.
Active Organization-
Inactive Organization
Eureka Therapeutics, Inc.Eureka Therapeutics, Inc.
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with ET190L1-ARTEMIS T cells(Eureka Therapeutics, Inc.)
NCT03379493 / TerminatedPhase 1
Open-label Phase I Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
NCT03895944 / Unknown statusEarly Phase 1IIT
Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1-ARTEMIS™2 in Relapsed, Refractory B Cell Leukemia and Lymphoma
NCT03415399 / CompletedPhase 1
Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1 ARTEMIS™ (Anti-CD19-ARTEMIS™) in Relapsed, Refractory B Cell Lymphoma
100 Clinical Results associated with ET190L1-ARTEMIS T cells(Eureka Therapeutics, Inc.)
Login to view more data
100 Translational Medicine associated with ET190L1-ARTEMIS T cells(Eureka Therapeutics, Inc.)
Login to view more data
100 Patents (Medical) associated with ET190L1-ARTEMIS T cells(Eureka Therapeutics, Inc.)
Login to view more data
100 Deals associated with ET190L1-ARTEMIS T cells(Eureka Therapeutics, Inc.)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD19 Positive B-Cell LeukemiaPhase 1
CN
Eureka Therapeutics, Inc.Eureka Therapeutics, Inc.
06 Dec 2017
CD19 positive B-Cell LymphomaPhase 1
CN
Eureka Therapeutics, Inc.Eureka Therapeutics, Inc.
06 Dec 2017
B-Cell LymphomaPhase 1
CN
Eureka Therapeutics, Inc.Eureka Therapeutics, Inc.
09 Sep 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free